



Assoc. Prof. HATİCE SEVİM NALKIRAN

Office Phone: [+90 212 300 9](tel:+902123009) Extension: 3212

Email: hatice.sevim@erdogan.edu.tr

Web: <https://avesis.erdogan.edu.tr/hatice.sevim>

International Researcher IDs

ScholarID: HRwxXTUAAAAJ

ORCID: 0000-0002-1115-2005

Publons / Web Of Science ResearcherID: AFK-7486-2022

Yoksis Researcher ID: 54833



Education

- I. Doctorate, University Of New South Wales, Faculty Of Medicine, Prince Of Wales Clinical School, Australia 2008 - 2012
- II. Undergraduate, Pamukkale University, Faculty Of Arts And Sciences, Department Of Biology, Turkey 2002 - 2006

Foreign Languages

- I. English, C1 Advanced

Certificates, Courses and Trainings

- I. Occupational Health and Safety, Radiation Safety in Laboratories, University of Sydney, Radiation Health Queensland, 2008
- II. Other, Biyolojik Arařtırmalarda Deneysel Hayvanların Kullanımı-IV/Training Program for Animal Use in Experimental Studies, Pamukkale University, Faculty of Medicine, 2006

Dissertations

- I. Doctorate, Determining Biological Factors Associated with Chemotherapy Response in Glioblastoma Patients, University Of New South Wales, 2012

Research Areas

Medicine, Medical Biology, Life Sciences, Molecular Biology and Genetics, Molecular Biology of Cancer, Health Sciences, Fundamental Medical Sciences, Natural Sciences

Academic Positions

- I. Assistant Professor, Recep Tayyip Erdogan University, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, 2018 - Continues
- II. Assistant Professor, Recep Tayyip Erdogan University, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, 2013 - 2018
- III. Research Assistant, Recep Tayyip Erdogan University, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, 2013 - 2013
- IV. Research Assistant, --Seçiniz--, University Of New South Wales, Lowy Cancer Research Centre, 2012 - 2012

Academic and Administrative Experience

- I. Akreditasyon, Sürekli Gelişim ve Yenilenme Kurulu Üyesi, Recep Tayyip Erdogan University, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, 2021 - Continues
- II. Erasmus Program Department Coordinator, Recep Tayyip Erdogan University, Tıp Fakültesi, 2020 - Continues
- III. Ölçme Değerlendirme Kurulu Üyesi, Recep Tayyip Erdogan University, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, 2019 - Continues
- IV. Ethics Committee Member, Recep Tayyip Erdogan University, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, 2013 - 2022
- V. Program Koordinatörü, Recep Tayyip Erdogan University, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, 2016 - 2017
- VI. Recep Tayyip Erdogan University, Tıp Fakültesi, Sağlık Bilimleri Enstitüsü, 2015 - 2016

Supervised Theses

- I. Sevim Nalkıran H., Mesane kanseri hastalarında CDC20 ve siklin B1 gen ekspresyon seviyelerinin incelenmesi, Postgraduate, İ.BİRİ(Student), 2023
- II. Sevim Nalkıran H., Investigation of the Prognostic Importance of Expressions of PD-1 and PD-L1 in Bladder Cancer Patients, Postgraduate, S.DURUR(Student), 2021

Jury Memberships

- I. Post Graduate, Post Graduate, Karadeniz Teknik Üniversitesi, June, 2024
- II. Post Graduate, Post Graduate, Tokat Gaziosmanpaşa Üniversitesi, January, 2024
- III. Doctorate, Doctorate, Recep Tayyip Erdoğan Üniversitesi, September, 2023
- IV. Post Graduate, Post Graduate, Recep Tayyip Erdoğan Üniversitesi, August, 2023
- V. Post Graduate, Post Graduate, Alanya Alaaddin Keykubat Üniversitesi, July, 2022
- VI. Post Graduate, Post Graduate, Recep Tayyip Erdoğan Üniversitesi, April, 2020

Journal articles indexed in SCI, SSCI, and AHCI

- I. **Repurposing ProTAME for Bladder Cancer: A Combined Therapeutic Approach Targeting Cell Migration and MMP Regulation**
Nalkıran İ., Sevim Nalkıran H.
BIOLOGY-BASEL, vol.14, no.3, pp.1-21, 2025 (SCI-Expanded)
- II. **Exploring the Therapeutic Potential of the DOT1L Inhibitor EPZ004777 Using Bioinformatics and Molecular Docking Approaches in Acute Myeloid Leukemia**
Kivrak M., Nalkıran İ., Sevim Nalkıran H.
CURRENT ISSUES IN MOLECULAR BIOLOGY, vol.47, no.3, pp.1-23, 2025 (SCI-Expanded)

- III. **Phytochemical Profile and Anticancer Potential of *Helichrysum arenarium* Extracts on Glioblastoma, Bladder Cancer, and Breast Cancer Cells**
Nalkiran İ., Sevim Nalkiran H.
PHARMACEUTICALS, vol.18, no.2, pp.1-18, 2025 (SCI-Expanded)
- IV. **Identification and Characterization of a Novel Rat MAVS Variant Modulating NFκB Signaling**
NALKIRAN İ., SEVİM NALKIRAN H.
BIOMOLECULES, vol.15, no.1, 2025 (SCI-Expanded)
- V. **CDC20 and CCNB1 Overexpression as Prognostic Markers in Bladder Cancer**
Sevim Nalkiran H., Biri I., Nalkiran İ., Uzun H., Durur S., Bedir R.
DIAGNOSTICS, vol.15, no.1, pp.1-21, 2025 (SCI-Expanded)
- VI. **An Electrochemical Immuno-cytosensor Modified with Nanofibers for the Determination of a Carcinoembryonic Antigen**
Yildizbakan Z., Altuntaş D., SEVİM NALKIRAN H., Aslan S., Mamuk A. E., Koçak Ç., Kurt Ş., NALKIRAN İ., Yener Ç., Ünlü C. G.
BIOCHIP JOURNAL, vol.18, no.3, pp.464-476, 2024 (SCI-Expanded)
- VII. **Inhibition of O6-methylguanine-DNA-methyltransferase (MGMT) by lomeguatrib reduces multiple myeloma cell viability and impairs DNA repair in MGMT-proficient cells**
Akcora-Yildiz D., ÖZKAN T., Cetintav B., Yukselten Y., Calis S., Sevim-Nalkiran H., Turkel N., Gunduz M., Ozen M., Beksac M., et al.
CHEMICAL BIOLOGY & DRUG DESIGN, vol.103, no.2, 2024 (SCI-Expanded)
- VIII. **The association of Sort1 expression with LDL subfraction and inflammation in patients with coronary artery disease**
Atak M., Sevim Nalkiran H., Bostan M., Uydu H. A.
Acta Cardiologica, vol.79, no.2, pp.159-166, 2024 (SCI-Expanded)
- IX. **Targeting the anaphase-promoting complex/cyclosome (APC/C) enhanced antiproliferative and apoptotic response in bladder cancer**
Sevim Nalkiran H., Akcora Yildiz D., Saydam F., Guzel A. I., Nalkiran İ.
Saudi Journal of Biological Sciences, vol.30, no.3, 2023 (SCI-Expanded)
- X. **Genetic variations in OLR1 gene associated with PCOS and atherosclerotic risk factors.**
Sahin S. B., Nalkiran İ., Ayaz T., Irfan Guzel A., Eldes T., Calapoglu T., Sevim Nalkiran H.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research, vol.71, no.2, pp.113-123, 2023 (SCI-Expanded)
- XI. **Prognostic importance of PD-L1 expression in bladder cancer patients.**
Durur S., Uzun H., Bedir R., Nalkiran İ., Nalkiran H. S.
Journal of cancer research and therapeutics, vol.19, no.Suppl 2, 2023 (SCI-Expanded)
- XII. **Development of MoS2 and Au nanoparticle including disposable CEA-based immuno-cytosensor platforms**
BAL ALTUNTAŞ D., SEVİM NALKIRAN H., ASLAN S., YOLCU Z.
CHEMICAL PAPERS, vol.76, no.8, pp.5217-5229, 2022 (SCI-Expanded)
- XIII. **Anticancer effects of a novel herbal combination as a potential therapeutic candidate against lung cancer**
SAYDAM F., Nalkiran H.
EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, vol.48, 2021 (SCI-Expanded)
- XIV. **Pelvic Radiation-Induced Testicular Damage: An Experimental Study at 1 Gray.**
RAKICI S., Guzel A. İ., TUMKAYA L., Nalkiran H. S., MERCANTEPE T.
Systems biology in reproductive medicine, vol.66, no.2, pp.89-98, 2020 (SCI-Expanded)
- XV. **Association of paraoxonase-1 L55M and Q192R polymorphisms with PCOS risk and potential risk factors for atherosclerosis**
Nalkiran H., Sahin S. B., Ayaz T., Nalkiran I., Guzel A. I., Eldes T., Yildiz Y.
BIOMARKERS IN MEDICINE, vol.13, no.4, pp.279-289, 2019 (SCI-Expanded)
- XVI. **Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory**

Factor (MIF)

Ha W., Sevim-Nalkiran H., ZAMAN A. M., MATSUDA K., Khasraw M., NOWAK A. K., Chung L., Baxter R. C., MCDONALD K. L.

SCIENTIFIC REPORTS, vol.9, 2019 (SCI-Expanded)

- XVII. **Is neuroglial antigen 2 a potential contributor to cilengitide response in glioblastoma?**
Nalkiran H., MCDONALD K. L.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.13, no.2, pp.329-336, 2017 (SCI-Expanded)
- XVIII. **Effects of nimesulide on the small intestine mucositis induced by methotrexate in rats**
ARSLAN A., ÖZÇİÇEK A., SÜLEYMAN B., ÇOBAN T. A., CIMEN F. K., Nalkiran H., KUZUCU M., ALTUNER D., Cetin N., SÜLEYMAN H.
EXPERIMENTAL ANIMALS, vol.65, no.4, pp.329-336, 2016 (SCI-Expanded)
- XIX. **Investigation of mucus obtained from different fish species on the acute pain induced with scalpel incision in paw of rats**
Cetin N., SULEYMAN B., KUYRUKLUYILDIZ U., Nalkiran H., KIRAN A., GENCOGLU S., DUZGUN A., Kurtoglu I. Z., Yarali O., Gul M. A., et al.
EXPERIMENTAL ANIMALS, vol.65, no.1, pp.77-85, 2016 (SCI-Expanded)
- XX. **Effects of Nimesulide on Oxidative Mucosal Injury Induced by Cisplatin in Rat Duodenum and Jejunum**
ÖZÇİÇEK F., ÇANKAYA M., CIMEN F. K., Kafa A. H. T., Nalkiran H., SÜLEYMAN B., ALTUNER D., Cetin N.
LATIN AMERICAN JOURNAL OF PHARMACY, vol.35, pp.1110-1115, 2016 (SCI-Expanded)
- XXI. **Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha?**
Sevim H., Parkinson J. F., McDonald K. L.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.137, no.11, pp.1705-1712, 2011 (SCI-Expanded)
- XXII. **In vivo effects of Urtica urens (dwarf nettle) on the expression of CYP1A in control and 3-methylcholanthrene-exposed rats**
Ozkarsli M., Sevim H., ŞEN A.
XENOBIOTICA, vol.38, no.1, pp.48-61, 2008 (SCI-Expanded)

Articles Published in Other Journals

- I. **Effects of Melaleuca alternifolia (Tea Tree) Oil and Vitamin E Combination on the Viability of Non-Small Cell Lung Cancer Cells**
Nalkiran İ., Sevim Nalkiran H.
Rize Medical Journal, vol.1, no.2, pp.34-48, 2024 (Peer-Reviewed Journal)
- II. **To Determine LDL Phenotypes Using Lipids, Lipoproteins, Apoproteins, and sdLDL Through Association Rule Mining**
Atak M., Kıvrak M., Sevim Nalkiran H., Uydu H. A., Şatroğlu Ö.
Journal of clinical practice and research, vol.45, no.6, pp.632-639, 2023 (ESCI)
- III. **Investigation of a Glioblastoma Risk-Associated SNP of the PTPRB Gene in Familial Glioblastoma**
Sevim Nalkiran H., Rakıcı S., Nalkiran İ.
Journal of oncological sciences, vol.9, no.1, pp.15-22, 2023 (Scopus)
- IV. **Comparison of DNA isolation methods from mammalian sperm cells and development of a new protocol**
SEVİM NALKIRAN H., NALKIRAN İ., RAKICI S., TÜMKAYA L., GÜZEL A. İ.
Medicine Science, vol.10, no.2, pp.440-443, 2021 (Peer-Reviewed Journal)
- V. **Effects of Hippophae rhamnoides extract on oxidative mucosal injury induced by cisplatin in rat jejunum.**
Arslan A., ÖZÇİÇEK F., KESKİN ÇİMEN F., SEVİM H., GÜLABOĞLU M., ÇETİN N., ÇOBAN T. A., KUZUCU M.

Biomedical Research-India, vol.29, no.2, pp.401-407, 2018 (Peer-Reviewed Journal)

- VI. **?Prevention of Carbon Tetrachloride-Induced Hepatotoxicity by Urtica urens in Rats.**
Sen A., Şahin B., Agus H. H., Bayav M., SEVİM NALKIRAN H., Semiz A.
JOURNAL OF APPLIED BIOLOGICAL SCIENCES, vol.1, no.3, pp.29-32, 2007 (Peer-Reviewed Journal)

Books

- I. **Otizm Spektrum Bozuklukları ve Sinema Terapi**
SEVİM NALKIRAN H.
in: TIP ve SANAT, Doç. Dr. Sema Yılmaz Rakıcı, Editor, Akademisyen Kitabevi, Ankara, pp.83-106, 2021

Papers Presented at Peer-Reviewed Scientific Conferences

- I. **Electrochemical Biosensor for Determination of Carcinoembryonic Antigen Biomarker Using Human Breast Ductal Adenocarcinoma, Human Ovarian Adenocarcinoma Cancer Cells**
Yıldızbakan Z., Bal Altuntaş D., Sevim Nalkıran H., Aslan S., Yolcu Z.
16th Nanoscience and Nanotechnology Conference, TÜRKİYE, 2022, Ankara, Turkey, 05 October 2022, (Summary Text)
- II. **An Electrochemical Immunosensor Modified with Nanofibers for the Determination of a Carcinoembryonic Antigen**
YILDIZBAKAN Z., BAL ALTUNTAŞ D., SEVİM NALKIRAN H., MAMUK A. E., KOÇAK Ç., ÜNLÜ C. G., ASLAN S.
16th Nanoscience and Nanotechnology Conference, Ankara, Turkey, 05 September 2022, (Summary Text)
- III. **Anticancer properties of a new herbal combination as a potential lung cancer treatment candidate**
SAYDAM F., SEVİM NALKIRAN H.
4th International Conference on Natural Products for Cancer Prevention and Therapy, Kayseri, Turkey, 18 December 2021, (Summary Text)
- IV. **Investigation of PD-L1 Gene Expression in Bladder Cancer Tissues**
Durur S., Uzun H., Bedir R., Nalkıran İ., Sevim Nalkıran H.
8th Multidisciplinary Cancer Research Congress, 16 - 17 January 2021, pp.102, (Summary Text)
- V. **Cytotoxic Effects of Melaleuca alternifolia (Tea Tree) Oil on A549 Non-Small Cell Lung Cancer and ARPE-19 Normal Epithelial Cells**
SEVİM NALKIRAN H.
5th International Hippocrates Congress on Medical and Health Sciences, Online, Turkey, 19 December 2020, (Summary Text)
- VI. **Prognostic role of PD-L1 expression in anti-PD-1/PD-L1 immunotherapy for bladder cancer patients, a meta-analysis**
Sevim Nalkıran H.
Eurasian Congress on Molecular Biotechnology, Trabzon, Turkey, 19 - 21 September 2019, pp.17, (Summary Text)
- VII. **Polikistik Over Sendromu Tanısı Almış Hastalarda Paraoksonaz 1 Genindeki Leu55Met ve Gln192Arg Polimorfizmlerinin Ateroskleroz riskiyle ilişkisinin Araştırılması**
SEVİM NALKIRAN H., AYAZ T., NALKIRAN İ., GÜZEL A. İ., ELDEŞ T., YILDIZ Y.
2. Ege Endokrin Hastalıklar ve Genetik Sempozyumu, Turkey, 23 - 25 February 2017, (Summary Text)
- VIII. **Y CHROMOSOME MICRODELITIONS IN 102 CASES: IS THE INCIDENCE OF ACQUIRED NON-OBSTRUCTIVE AZOOSPERMIA INCREASING?**
UZUN H., SEVİM NALKIRAN H., AKÇA N., EREN H., NALKIRAN İ., SAYDAM F., GÜZEL A. İ.
ESAU Meeting Bodrum Turkey, Muğla, Turkey, 21 May 2017, pp.84, (Summary Text)
- IX. **Y Chromosome Microdeletions in 102 cases: Is the Incidence of Acquired Non-obstructive Azoospermia Increasing?**

UZUN H., SEVİM NALKIRAN H., AKÇA N., EREN H., NALKIRAN İ., SAYDAM F., GÜZEL A. İ.

ESAU Meeting, Muğla, Turkey, 21 May 2017, (Summary Text)

- X. **Effect of treating glioblastoma with a cytokine inhibitor, ibudilast, in combination with temozolomide on survival in a patient-derived xenograft model.**
McDonald K. L., Ha W., Sevim H., Matsuda K., Khasraw M.
53rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2017, vol.35, (Summary Text)
- XI. **EFFECT OF SORTILIN GEN EXPRESSION ON LDL SUBFRACTIONS AND SEVERITY OF CORONARY ARTERY DISEASE**
UYDU H. A., ATAK M., BOSTAN M., SEVİM NALKIRAN H., MALKOÇ M., PINARBAŞ E., KARAKAŞ S., HÜNER M., AKYILDIZ K., YILMAZ A.
85th Congress of the European Atherosclerosis Society, Brisbane, Australia, 23 - 26 April 2017, vol.11, no.263, pp.0-104, (Summary Text)
- XII. **Simultane Familial Glioblastom: İki Kardeş Glioblastom Vakası**
RAKICI S., SEVİM NALKIRAN H., ÇETİN B., BEDİR R.
22. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 19 - 23 April 2017, pp.153, (Full Text)
- XIII. **Investigation of Association Between Paraoxonase-1 L55M (RS854560) and Q192R (RS662) Polymorphisms and Potential Atherosclerotic Risk Factors in PCOS Patients Patients (Polikistik Over Sendromu Tanısı Almış Hastalarda Paraoksonaz 1 Genindeki Leu55Met ve Gln192Arg Polimorfizmlerinin Ateroskleroz riskiyle ilişkisinin Araştırılması)**
SEVİM NALKIRAN H., AYAZ T., NALKIRAN İ., GÜZEL A. İ., DURAKOĞLUGİL T., YILDIZ Y.
2. Ege Endokrin Hastalıklar ve Genetik Sempozyumu, İzmir, Turkey, 23 - 25 February 2017, vol.9, pp.27, (Summary Text)
- XIV. **Repurposing Ibudilast in combination with temozolomide for glioblastoma**
McDonald K., Ha W., SEVİM NALKIRAN H., Khasraw M.
21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, Scottsdale, Arizona, Arizona, United States Of America, 17 - 20 November 2016, vol.18, (Summary Text)
- XV. **Repurposing Ibudilast in combination with temozolomide for glioblastoma**
McDonald K., Ha W., SEVİM NALKIRAN H., Chung L., Baxter R., Khasraw M.
13th Asian Society for Neuro-Oncology (ASNO) Meeting/9th COGNO Annual Scientific Meeting, Sydney, Australia, 11 - 14 September 2016, pp.67, (Summary Text)
- XVI. **MIF/CD74 guided therapeutic strategy for relapsed glioblastoma patients**
McDonald K. L., SEVİM NALKIRAN H., Ha W., Chung L., Baxter R.
105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), California, United States Of America, 5 - 09 April 2014, vol.74, (Summary Text)
- XVII. **MIF-CD74 GUIDED THERAPEUTIC STRATEGY FOR THE UPFRONT TREATMENT OF GBM PATIENTS WITH AN UNMETHYLATED MGMT PROMOTER**
McDonald K. L., Ha W., Sevim H.
20th International Conference on Brain Tumor Research and Therapy, California, United States Of America, 20 - 22 July 2014, vol.16, (Summary Text)
- XVIII. **Improved Responsiveness to Temozolomide by Blocking MIF Expression in Glioblastoma**
McDonald K. L., SEVİM NALKIRAN H.
Worldwide Innovative Networking in Personalized Cancer Medicine WIN 2013 Symposium-Personal Cancer Medicine: From Innovation to implementation, Paris, France, 10 - 12 July 2013, pp.7, (Full Text)
- XIX. **Aberrant expression of low molecular weight proteins associated with response to conventional concurrent chemoradiotherapy treatment and overall survival?**
SEVİM NALKIRAN H., Chung L., Wheeler H. R., Baxter R. C., McDonald K. L.
European Association of Neuro-oncology (EANO) 10th meeting, Marsilya, France, 6 - 07 September 2012, no.14, (Summary Text)
- XX. **Aberrant expression of Low-molecular-weight proteins associated with response to conventional concurrent chemoradiotherapy treatment**

SEVİM NALKIRAN H., Chung L., Wheeler H. R., Baxter R. C., McDonald K. L.

16th Annual Scientific Meeting & Education Day of the Society for Neuro-Oncology, Garden Grove, United States Of America, 17 - 20 November 2011, vol.13, (Full Text)

XXI. Protein biomarker discovery in glioblastoma using SELDI-TOF-MS

SEVİM NALKIRAN H., Chung L., Wheeler H. R., Baxter R. C., McDonald K. L.

102nd Annual Meeting of the American Association for Cancer Research, Orlando, United States Of America, 2 - 06 April 2011, vol.71, no.5094, pp.71, (Full Text)

XXII. Determining Biological Factors Associated with chemotherapy response in Glioblastoma Patients?

SEVİM NALKIRAN H., Maleki S., Messina M., Robinson B. G., McDonald K. L.

XXVIth Annual Scientific Research Meeting, Sydney, Australia, 25 November 2009, pp.51, (Full Text)

XXIII. In vivo effects of Urtica urens seed extracts on the cytochrome P450-dependent monooxygenases in the liver, lung and kidney of control and 3-methylcholanthrene-exposed rats

SEN A., Agus H. H., Bayav M., SEVİM NALKIRAN H.

14th North American ISSX Meeting, Puerto Rico, United States Of America, 22 - 26 October 2006, vol.38, pp.55-56, (Full Text)

XXIV. Karaciğer Koruyucu Urtica urens: Sıçanlarda Karbontetraklorür'ün Neden Olduğu Karaciğer Toksisitesinin U. urens ile Giderilmesi

Sen A., Şahin B., Bayav M., Agus H. H., SEVİM NALKIRAN H., Semiz A.

18. Ulusal Biyoloji Kongresi, Aydın, Turkey, 26 - 30 June 2006, no.154, pp.59, (Full Text)

XXV. In vivo assessment of Urtica urens supplementation on rat xenobiotic metabolizing enzymes

Sen A., Agus H. H., Bayav M., SEVİM NALKIRAN H.

Federation of European Biochemical Societies, İstanbul, Turkey, 25 - 29 June 2006, vol.273, pp.300, (Full Text)

Funded Projects

- I. NALKIRAN İ., SEVİM NALKIRAN H., Project Supported by Higher Education Institutions, Lavandula stoechasın Kanser Hücrelerinin İnvazyonunu İnhibe Edici Etkilerinin İncelenmesi, 2025 - Continues
- II. SEVİM NALKIRAN H., NALKIRAN İ., Can E., Project Supported by Higher Education Institutions, Tannik Asidin Glioblastoma Sferoidlerinde Sitotoksik Apoptotik ve Ferroptotik Etkilerinin İncelenmesi, 2025 - Continues
- III. UZUN F., SEVİM NALKIRAN H., NALKIRAN İ., SÜMER F., Project Supported by Higher Education Institutions, Çeşitli Anti-glokom İlaçların Lens Epitel Hücrelerinin Epitelyal-Mezenkimal Geçışı ve Migrasyonu Üzerindeki Etkileri, 2025 - Continues
- IV. İrtegin Kandemir S., Özşener Özekinci S., Onat S., Sevim Nalkıran H., Akçora Yıldız D., Oruç Z., Şeker U., Kavak D. E., TÜBİTAK Project, Investigation of the Therapeutic Target Potential of Mitochondrial Proteases in Pleural Mesothelioma, 2024 - 2027
- V. Bal Altuntaş D., Kara Subaşat H., Sevim Nalkıran H., Nalkıran İ., Aslan S., Mamuk A. E., Koçak Ç., TÜBİTAK Project, Development of a New 3D Glioblastoma Tumor-Microenvironment Interaction Model and the Establishment of Electrochemical Platforms, 2022 - 2024
- VI. Sevim Nalkıran H., Nalkıran İ., TÜBİTAK Project, Investigation of Targeting the MAVS Signaling Pathway as a Potential Cancer Immunotherapy Approach, 2020 - 2024
- VII. SEVİM NALKIRAN H., NALKIRAN İ., Project Supported by Higher Education Institutions, Lavandula stoechas esansiyel yağ ve özütünün kanser hücreleri üzerinde potansiyel sitotoksik ve anti-metastatik etkilerinin araştırılması, 2020 - 2023
- VIII. SEVİM NALKIRAN H., Durur S., Project Supported by Higher Education Institutions, Mesane Kanseri Hastalarında PD1 ve PDL1 Ekspresyonlarının Prognostik Öneminin İncelenmesi, 2020 - 2021
- IX. SEVİM NALKIRAN H., NALKIRAN İ., SAYDAM F., GÜZEL A. İ., Project Supported by Higher Education Institutions, Mesane kanseri hücrelerinin standart kemoterapi rejimi ve inhibitör içeren kombine terapiye karşı cevabının araştırılması, 2017 - 2020
- X. UYDU H. A., PINARBAŞ E., AKYILDIZ K., ATAK M., SEVİM NALKIRAN H., HÜNER M., Project Supported by Higher

Education Institutions, Koroner Arter Hastalarında Sortilin Gen Bölgesiyle İlişkili Non-coding rs599839 Gen Polimorfizimin Lipoprotein Alt Fraksiyonlar İle Olan İlişkisinin İncelenmesi, 2014 - 2018

- XI. RAKICI S., TÜMKAYA L., GÜZEL A. İ., SEVİM NALKIRAN H., Project Supported by Higher Education Institutions, Düşük doz radyasyonun germ hücrelerinde oluşturduğu genetik ve histopatolojik değişiklikler., 2014 - 2017
- XII. SEVİM NALKIRAN H., NALKIRAN İ., AYAZ T., GÜZEL A. İ., Project Supported by Higher Education Institutions, Polikistik over sendromu tanısı almış hastalarda paraoksonaz 1 genindeki Leu55Met ve Gln192Arg polimorfizmlerinin ateroskleroz riskiyle ilişkisinin araştırılması, 2013 - 2017

Memberships and Roles in Scientific Organizations

- I. American Association for Cancer Research, Member, 2024 - Continues, United States Of America
- II. Moleküler Kanser Araştırma Derneği, Member, 2022 - Continues, Turkey
- III. European Association for Cancer Research, Member, 2022 - Continues, England
- IV. Tıbbi Biyoloji ve Genetik Derneği, Member, 2013 - Continues
- V. American Association for Cancer Research, Member, 2011 - 2020, United States Of America
- VI. European Association for Cancer Research, Member, 2013 - 2018, United Kingdom

Peer Reviews in Scientific Publications

- I. Oncotargets and therapy, SCI Journal, September 2016
- II. Journal of Obstetrics and Gynaecology Research , SCI Journal, February 2016
- III. Oncotargets and therapy, SCI Journal, October 2014
- IV. Oncotargets and therapy, SCI Journal, July 2014
- V. Oncotargets and therapy, SCI Journal, March 2014
- VI. Pharmacogenomics and Personalized Medicine, Other Indexed Journal, November 2013
- VII. Oncotargets and therapy, SCI Journal, October 2013
- VIII. Oncotargets and therapy, SCI Journal, March 2013

Metrics

Publication: 57
Citation (WoS): 99
H-Index (WoS): 6
H-Index (Scopus): 5

Congress and Symposium Activities

- I. Eurasian Congress on Molecular Biotechnology, Invited Speaker, Trabzon, Turkey, 2020
- II. Clinical Oncological Society of Australia (COSA) Neuro-Oncology Clinical Professional Day, Attendee, Sydney, Australia, 2012
- III. The 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Collaboration with the AANS/CMS Section on Tumors (MCOS 1002), Attendee, California, United States Of America, 2011

Scholarships

- I. 1416 Sayılı Kanun Uyarınca Yurtdışında Lisansüstü Öğrenim Bursu, Ministry of Education, 2006 - 2012
- II. Round 1, Prince of Wales Clinical School (POWCS), University, 2011 - 2011
- III. Round 1, Postgraduate Research Support Scheme (PRSS), University, 2011 - 2011